Novel Drug & Emergent Therapeutics | Radiology & imaging | MRI
Neurophet's AI-Powered AQUA Software Receives FDA Clearance for Advanced Multiple Sclerosis Analysis
Time to read:01:52
Originally published: 25 November 2024
Source: Neurophet
Type of article: Novel Drug & Emergent Therapy News
MedED Catalogue Reference: MNDAI002
Category: Radiology
Crossreference: Mutliple Sclerosis, Artifical Intelligence
Keywords: MS, Imaging, neurodegenerative diseases, white matter hyperintensities
| Product Category | Product Name | Company | Status |
|---|---|---|---|
| 501k, FDA Approved |
25 November 2024. PRNewire
This milestone comes as the software introduces an innovative feature for analyzing multiple sclerosis (MS), a chronic and often debilitating condition of the central nervous system.
Access Original Press Release
25 November 2024 | PR Newswire | Neurophet Secures FDA 510(k) Clearance for Multiple Sclerosis Analysis with 'Neurophet AQUA
Disclaimer
This article is compiled from a variety of resources. Every effort has been made to attribute quotes and content correctly. Where possible, all information has been independently verified. The Medical Education Network bears no responsibility for any inaccuracies which may occur from the use of third-party sources. If you have any queries regarding this article contact us
Fact-checking Policy
The Medical Education Network makes every effort to review and fact-check the articles used as source material in our summaries and original material. We have strict guidelines in relation to the publications we use as our source data, favouring peer-reviewed research wherever possible. Every effort is made to ensure that the information contained here is an accurate reflection of the original material. Should you find inaccuracies, out of date content or have any additional issues with our articles, please make use of the contact us form to notify us.
